Common TitleTRI-003
Official Title A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection
Phase Phase II
ClinicalTrials.gov NCT00002228
Treatments
Enfuvirtide
Enfuvirtide
Tradename:FuzeonOther Names:T-20Class:Entry InhibitorsCategories PharmacologyTreatment-ExperiencedGeneral Pharmacology
Funding
IndustryTrimeris
References
- Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002;18:685-93.